Cohance Lifesciences Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Cohance Lifesciences Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $13.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cohance Lifesciences Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $13.6M Trade | TransData Nexus

Cohance Lifesciences Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $13.6M Total Trade · DGFT Verified

Cohance Lifesciences Limited is an Indian pharmaceutical exporter with a total trade value of $13.6M across 4 products in 4 therapeutic categories. Based on 278 verified export shipments from Indian Customs (DGFT) records, Cohance Lifesciences Limited is the #1 Indian exporter in 1 product including Itraconazole. Top exports include Isosorbide ($7.0M), Itraconazole ($3.5M), Spironolactone ($1.6M).

Cohance Lifesciences Limited — Export Portfolio & Destination Treemap

Cohance Lifesciences Limited pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Cohance Lifesciences Limited? — Company Overview & Market Position

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, was established in 1989 and is headquartered in Hyderabad, India. The company specializes in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (APIs), specialty chemicals, and formulated drugs. Its diverse product portfolio includes small molecule APIs, advanced intermediates, antibody drug conjugates, high-purity oligonucleotide building blocks, pellets, finished dosage forms, and specialty chemicals such as agrochemicals.

In May 2025, the company rebranded from Suven Pharmaceuticals Limited to Cohance Lifesciences Limited, reflecting its expanded capabilities and strategic direction. As of March 2026, Cohance Lifesciences Limited is a publicly listed entity on the National Stock Exchange of India (NSE) under the ticker symbol COHANCE and on the Bombay Stock Exchange (BSE) under the ticker symbol 543064. The company has a paid-up capital of ₹3,432.79 crore and an authorized capital of ₹3,499.94 crore.

What Does Cohance Lifesciences Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Isosorbide$7.0M

Product Portfolio — Top 4 by Export Value

Cohance Lifesciences Limited exports 4 pharmaceutical products across 4 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Isosorbide	Cardiovascular	$7.0M	141	15.7%	2
2	Itraconazole	Antifungals	$3.5M	69	12.6%	1
3	Spironolactone	Diuretics	$1.6M	32	0.8%	8
4	Tetracycline	Antibiotics	$1.5M	36	8.6%	4

Cohance Lifesciences Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $13.6M. The company is the #1 Indian exporter in 1 product: Itraconazole. The top category is Cardiovascular (52.0% of portfolio), followed by Antifungals (25.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Cohance Lifesciences Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Cohance Lifesciences Limited operates multiple manufacturing facilities across India, specializing in the production of APIs and finished pharmaceutical formulations. These facilities are equipped with advanced technologies to ensure high-quality standards and compliance with international regulatory requirements. The company's manufacturing units are strategically located to serve both domestic and international markets, facilitating efficient distribution and supply chain management.

3Key Leadership

The leadership team at Cohance Lifesciences Limited is headed by Managing Director and Chief Executive Officer, Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju. The Chief Financial Officer is Himanshu Agarwal, who oversees the company's financial operations. Other key executives include Yann D'Herve, Chief Executive Officer of the CDMO Business, and K.P. Ravinatha Shetty, Platform Chief Operating Officer. The company also has a dedicated Head of Investor Relations, Cyndrella Carvalho, and a Chief Quality and Compliance Officer, Dr. K. Nagendra Babu.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Cohance Lifesciences Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Cohance Lifesciences Limited has a significant presence in regulated markets, including the United States, Europe, the United Kingdom, and Australia. The company has obtained approvals for its APIs and finished dosage forms from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. These approvals enable Cohance to market its products in these regions, adhering to stringent quality and safety standards. The company's commitment to regulatory compliance is further demonstrated by its adherence to Good Manufacturing Practices (GMP) and other relevant guidelines.

2Emerging Markets

Cohance Lifesciences Limited has strategically expanded its footprint into emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), facilitating access to these regions and enhancing its global reach. By obtaining WHO prequalification, Cohance ensures that its products meet international quality standards, thereby gaining the trust of healthcare providers and patients in these markets.

3Geographic Strategy

Cohance Lifesciences Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Cohance Lifesciences Limited's manufacturing facility in Hyderabad, India, is registered with the U.S. Food and Drug Administration (FDA). The company has received a warning letter from the FDA dated January 30, 2026, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The FDA identified issues related to inadequate investigations into product quality complaints and insufficient cleaning and maintenance of manufacturing equipment. Cohance has acknowledged these observations and is committed to implementing corrective actions to address the FDA's concerns.

2WHO & EU GMP

Cohance Lifesciences Limited's manufacturing facilities comply with World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards. The company's products are prequalified by the WHO, ensuring they meet international quality standards. This compliance facilitates access to global markets and underscores Cohance's commitment to maintaining high-quality manufacturing practices.

3CDSCO & Indian Regulatory

Cohance Lifesciences Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Cohance Lifesciences Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products and services. The company's focus on complex chemistries and end-to-end contract development and manufacturing organization (CDMO) services differentiates it from competitors. Cohance's extensive product portfolio, including APIs, advanced intermediates, and finished dosage forms, positions it as a comprehensive solution provider in the pharmaceutical sector.

2Key Differentiators

Cohance Lifesciences Limited's key differentiators include its expertise in complex chemistries, robust research and development capabilities, and a comprehensive product portfolio spanning APIs, advanced intermediates, and finished dosage forms. The company's commitment to quality and regulatory compliance, as evidenced by its adherence to WHO and EU GMP standards, further distinguishes it in the pharmaceutical industry.

3Strategic Position

Cohance Lifesciences Limited's strategic direction focuses on expanding its presence in both regulated and emerging markets. The company's commitment to quality, regulatory compliance, and sustainability positions it as a trusted partner for pharmaceutical companies seeking reliable manufacturing solutions. Cohance's ongoing efforts to address regulatory observations and implement corrective actions demonstrate its dedication to continuous improvement and long-term growth.

Buyer Due Diligence Brief — Evaluating Cohance Lifesciences Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Cohance Lifesciences Limited has a track record of supplying pharmaceutical products to various international markets. The company's export volume and consistency are supported by its compliance with international regulatory standards, including WHO and EU GMP. While the FDA's warning letter in January 2026 highlights areas for improvement, Cohance's commitment to corrective actions and quality assurance indicates a focus on maintaining reliability and trustworthiness as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Cohance Lifesciences Limited as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the WHO Good Manufacturing Practices certification to ensure adherence to international quality standards.

Frequently Asked Questions — Cohance Lifesciences Limited

How many pharmaceutical products does Cohance Lifesciences Limited export from India?

Cohance Lifesciences Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Isosorbide ($7.0M), Itraconazole ($3.5M), Spironolactone ($1.6M), Tetracycline ($1.5M). Total export value is $13.6M.

What is Cohance Lifesciences Limited's total pharmaceutical export value?

Cohance Lifesciences Limited's total pharmaceutical export value is $13.6M, based on 278 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Cohance Lifesciences Limited the #1 Indian exporter?

Cohance Lifesciences Limited is the #1 Indian exporter in 1 products: Itraconazole (12.6% market share).

What therapeutic categories does Cohance Lifesciences Limited cover?

Cohance Lifesciences Limited exports across 4 therapeutic categories. The largest are Cardiovascular (52.0%, 1 products), Antifungals (25.4%, 1 products), Diuretics (11.8%, 1 products).

Get Full Cohance Lifesciences Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.